Everolimus, Lutetium-177 DOTATATE and Sunitinib for Advanced, Unresectable or Metastatic Neuroendocrine Tumours With Disease Progression: A Systematic Review and Cost-Effectiveness Analysis

Health Technology Assessment - United Kingdom
doi 10.3310/hta22490
Full Text
Abstract

Available in full text

Date
Authors
Publisher

National Institute for Health Research

Related search

PCN63 Cost-Effectiveness of Sunitinib in Patients With Advanced or Metastatic Pancreatic Neuroendocrine Tumors in Portugal

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Imatinib for the Treatment of Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumours: Systematic Review and Economic Evaluation

Health Technology Assessment
MedicineHealth Policy
2005English

Matching Adjusted Indirect Comparison of Sunitinib and Everolimus for the Treatment of Pancreatic Neuroendocrine Tumours (PNETS)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2017English

Cost-Effectiveness Analysis of Sunitinib Versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore

International Journal of Technology Assessment in Health Care
Health Policy
2019English

Pazopanib Has Equivalent Anti-Tumor Effectiveness and Lower Total Costs Than Sunitinib for Treating Metastatic or Advanced Renal Cell Carcinoma: A Meta-Analysis

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Pcn165 - Cost-Effectiveness of Sorafenib for Metastatic Renal Cell Carcinoma: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Radiofrequency Ablation for Unresectable Locally Advanced Pancreatic Cancer: A Systematic Review

HPB
HepatologyGastroenterology
2014English

The Clinical Effectiveness and Cost-Effectiveness of Enzyme Replacement Therapy for Gaucher’s Disease: A Systematic Review

Clinical Governance: An International Journal
2007English

Therapeutic Efficacy and Dosage of Pazopanib for Metastatic or Unresectable Advanced Soft Tissue Sarcomas

Chemotherapy: Open Access
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy